Pembrolizumab trials for Melanoma

All Pembrolizumab trials · All Melanoma trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Melanoma

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
  NCT02621021 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
  NCT07448831 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
  NCT03829254 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
  NCT05859074 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · 16 locations
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
  NCT06880549 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
  NCT07749586 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
  NCT06797297 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
  NCT06624644 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
  NCT05913388 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
  NCT07422779 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
  NCT04697576 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
  NCT07092670 · Phase: Not specified · Ages: Up to 40 Years · Sex: Female · 10 locations
• Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
  NCT06771544 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Combination Immunotherapy for Stage III Melanoma
  NCT03842943 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
  NCT07349303 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
  NCT06906822 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Palbociclib and Pembrolizumab In Central Nervous System Metastases
  NCT02896335 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
  NCT07223424 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
  NCT04318717 · Phase: Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
  NCT05155033 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
  NCT05492682 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Sitagliptin With Pembro in RCC and Melanoma
  NCT07634380 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
  NCT07287917 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
  NCT07565285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 81 locations

Common questions

How many trials study Pembrolizumab for Melanoma?

34 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.